专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014125164A1 A METHOD FOR DETERMINING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) RELATED BIOMARKERS, A METHOD TO MONITOR THE DEVELOPMENT AND TREATMENT OF ARDS IN A PATIENT 审中-公开
标题翻译：用于确定急性呼吸道综合征（ARDS）相关生物标志物的方法，监测患者中ARDS发展和治疗的方法
公开(公告)号：WO2014125164A1
公开(公告)日：2014-08-21
申请号：PCT/FI2014/050051
申请日：2014-01-22
申请人： FARON PHARMACEUTICALS OY , MAKSIMOW, Mikael , SALMI, Marko , JALKANEN, Markku , JALKANEN, Sirpa
发明人： MAKSIMOW, Mikael , SALMI, Marko , JALKANEN, Markku , JALKANEN, Sirpa
IPC分类号： G01N33/573 , G01N30/90 , C07K14/705 , C07K14/565 , C12N9/16
CPC分类号： G01N33/573 , A61K38/215 , G01N30/90 , G01N33/6884 , G01N33/6893 , G01N2333/70596 , G01N2333/916 , G01N2800/125 , G01N2800/52 , G01N2800/60
摘要： This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favourable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favourable change or starts to show an unfavourable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS. The invention concerns further a method for simultaneous determination of a multiple of biomarkers in a sample from a patient, wherein said biomarkers are related to ARDS. The level or the activity of the biomarkers is determined. The invention also concerns a diagnostic kit useful for carrying out the method, particularly a kit comprising a chip, such as a microarray suitable for use in biochip technology.
摘要翻译：本发明涉及监测患者ARDS发展和治疗ARDS的方法。用于监测ARDS发展的方法是基于将在稍后时间点绘制的样品中获得的生物标志物的水平或活性与在先前时间点绘制的样品中相同生物标志物的水平或活性进行比较。某种生物标志物的水平或活性的有利变化表示疾病的消退（患者的恢复），相反地，某种生物标志物的水平或活性的不利变化代表疾病的恶化。例如，如果所监测的一种或多种生物标志物的水平或活性停止显示有利的变化或开始显示不利的变化，则通过施用可用于治疗ARDS的治疗活性剂来增强患者的治疗。本发明还涉及用于同时测定来自患者的样品中多个生物标志物的方法，其中所述生物标志物与ARDS相关。确定生物标志物的水平或活性。本发明还涉及可用于实施该方法的诊断试剂盒，特别是包含芯片的试剂盒，例如适用于生物芯片技术的微阵列。

2. 发明申请

WO2009053523A1 A NEW BIOMARKER FOR MONITORING DEVELOPMENT OF DISEASES AND ASSESSING THE EFFICACY OF THERAPIES 审中-公开
标题翻译：用于监测疾病发展和评估治疗效果的新生物标志物
公开(公告)号：WO2009053523A1
公开(公告)日：2009-04-30
申请号：PCT/FI2008/050576
申请日：2008-10-15
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
发明人： JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
IPC分类号： G01N33/573 , C07K14/705 , C12N9/16 , G01N33/574
CPC分类号： G01N33/57484 , G01N2333/70596 , G01N2800/245 , G01N2800/324 , G01N2800/56
摘要： The invention concerns a method for monitoring the development of a disease in a patient, or for assessing the efficacy of a cytokine therapy or a statin therapy in a patient, in which methods CD73 in a tissue fluid drawn from said patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.
摘要翻译：本发明涉及用于监测患者疾病发展或用于评估患者中的细胞因子疗法或他汀类药物治疗的功效的方法，其中从所述患者抽取的组织液中的CD73用作生物标志物。本发明还涉及从个体组织液中抽出的样品中测定CD73蛋白的方法。

3. 发明申请

WO2006128951A1 COMPOSITIONS FOR TARGETING AMINE OXIDASES IN VIVO 审中-公开
标题翻译：用于在体液中靶向氨氧化物的组合物
公开(公告)号：WO2006128951A1
公开(公告)日：2006-12-07
申请号：PCT/FI2006/000144
申请日：2006-05-04
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , SALMI, Marko
发明人： JALKANEN, Sirpa , SALMI, Marko
IPC分类号： C07K7/06 , A61K38/08 , A61K47/00 , C12N9/02
CPC分类号： C07K7/06 , A61K38/08 , A61K47/64
摘要： This invention relates to a diagnostic compositions for targeting an amine oxidase enzyme in vivo, said composition comprising a labelled peptide having the capability to bind to said enzyme. Further, the invention concerns a pharmaceutical composition for use to modulate the activity of an amine oxidase enzyme, said composition comprising a peptide having the capability to bind to said enzyme, wherein said peptide further is conjugated to a therapeutically active agent. Still further, the invention concerns a novel peptide and its uses, especially as VAP-1 inhibitor.
摘要翻译：本发明涉及用于在体内靶向胺氧化酶的诊断组合物，所述组合物包含具有结合所述酶的能力的标记肽。此外，本发明涉及用于调节胺氧化酶的活性的药物组合物，所述组合物包含具有结合所述酶的能力的肽，其中所述肽进一步与治疗活性剂缀合。此外，本发明涉及新型肽及其用途，特别是作为VAP-1抑制剂。

4. 发明申请

WO2010122217A1 A NOVEL CELL AND THERAPEUTICAL AND DIAGNOSTICAL METHODS BASED THEREON 审中-公开
标题翻译：基于此的新型细胞和治疗与诊断方法
公开(公告)号：WO2010122217A1
公开(公告)日：2010-10-28
申请号：PCT/FI2010/050266
申请日：2010-04-06
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
发明人： JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
IPC分类号： C07K14/05 , A61K39/395 , A61P35/00
CPC分类号： C12N15/1138 , A61K31/58 , A61K35/15 , A61K38/17 , A61K38/202 , A61K38/2026 , A61K2039/505 , C07K16/28 , C12N15/115 , C12Q1/6883 , C12Q1/6886
摘要： The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.
摘要翻译：本发明涉及一种衍生自人体的新型细胞，其中所述细胞包含Clever-1受体; 涉及一种影响个体的免疫系统和用于治疗与免疫系统的功能有关的疾病或病症的方法，以及用于筛选可能对抗Clever-1疗法或诊断的癌症患者的方法怀孕并发症或估计孕妇出现并发症的风险。

5. 发明申请

WO2005063261A1 AMINOGLYCOSIDE ANTIBIOTICS FOR USE AS VAP-1/SSAO INHIBITORS 审中-公开
标题翻译：用作VAP-1 / SSAO抑制剂的氨基丁糖抗体
公开(公告)号：WO2005063261A1
公开(公告)日：2005-07-14
申请号：PCT/FI2004/000772
申请日：2004-12-17
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
发明人： JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
IPC分类号： A61K31/702
CPC分类号： A61K31/7048 , A61K31/7034
摘要： The present invention concerns the use of a compound comprising one or more sugar moieties, which optionally are aminosubstitutes, and possibly other moieties, wherein said compound is a molecule comprising at least two aminosubstituents, said aminosubstituents being primary, secondary or tertiary amino groups, wherein said aminosubstituents are either attached to one single sugar moiety or attached to several sugar moieties or other moieties of the molecule, or to chains connecting two moieties or to chains being substituents to the molecule, for the manufacture of a pharmaceutical preparation useful as an agent capable of influencing an amine oxidase enzyme activity, more particularly inhibiting VAP-1/SSAO activity. The preferred compounds are aminoglycoside antibiotics, e.g., streptomycin, netilmicin, geneticin, gentamicin, puromycin, tobramycin and amikacin. The preferred conditions to be treated are inflammatory diseases or conditions, diseases related to carbohydrate metabolism, diseases related to aberrations in adipocyte differentiation or function or smooth muscle cell function, and vascular diseases.
摘要翻译：本发明涉及包含一个或多个糖部分的化合物（其任选为氨基化合物）以及可能的其它部分的用途，其中所述化合物是包含至少两个氨基取代基的分子，所述氨基取代基是伯，仲或叔氨基，其中所述氨基取代基连接到一个单个糖部分或连接到该分子的几个糖部分或其它部分，或连接到分子的两个部分或连接于链的取代基的链，用于制备可用作药剂的药物制剂影响胺氧化酶活性，更特别地抑制VAP-1 / SSAO活性。优选的化合物是氨基糖苷类抗生素，例如链霉素，净霉素，遗传霉素，庆大霉素，嘌呤霉素，妥布霉素和阿米卡星。待治疗的优选条件是炎性疾病或病症，与碳水化合物代谢有关的疾病，与脂肪细胞分化或功能或平滑肌细胞功能异常有关的疾病和血管疾病。

6. 发明申请

WO2003057130A2 COMMON LYMPHATIC ENDOTHELIAL AND VASCULAR ENDOTHELIAL RECEPTOR-1 (CLEVER-1) AND USES THEREOF 审中-公开
标题翻译：普通淋巴管内皮细胞和血管内皮受体1（CLEVER-1）及其用途
公开(公告)号：WO2003057130A2
公开(公告)日：2003-07-17
申请号：PCT/FI2003/000010
申请日：2003-01-08
申请人： JALKANEN, Sirpa , IRJALA, Heikki , SALMI, Marko
发明人： JALKANEN, Sirpa , IRJALA, Heikki , SALMI, Marko
IPC分类号： A61K
CPC分类号： C07K14/7056 , A61K2039/505 , C07K16/28
摘要： A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.
摘要翻译：描述了一种新型蛋白质普通淋巴管内皮和血管内皮细胞受体-1（CLEVER-1）。 CLEVER-1介导白细胞和恶性细胞与血管和淋巴样内皮细胞的结合。 CLEVER-1是第一个报道介导淋巴结流入和流出的蛋白质。还提供了通过提供CLEVER-1结合抑制剂来治疗炎症和预防恶性细胞转移的方法。

7. 发明申请

WO2012064277A1 Transition device 审中-公开
标题翻译：过渡装置
公开(公告)号：WO2012064277A1
公开(公告)日：2012-05-18
申请号：PCT/SE2011/051359
申请日：2011-11-11
申请人： Flexlink Components AB , SALMI, Marko , BOKESAND, Linus
发明人： SALMI, Marko , BOKESAND, Linus
IPC分类号： B65G47/31 , B65G13/02 , B65G15/14 , B65G15/20 , B65G43/08
CPC分类号： B65G47/681 , B65G47/31
摘要： Transition device that is adapted to receive objects from a first horizontal conveyor having a first speed and to feed the objects to a second horizontal conveyor having a second speed and to position the objects at predefined positions on the second conveyor, where the incoming objects of the first conveyor have a variable spacing, and where the transition device is adapted to accelerate the objects individually from the first speed to the second speed depending on the position of the object on the fist conveyor. The advantage of the invention is that objects having a variable spacing from a first conveyor can be positioned on a second conveyor at predefined positions.
摘要翻译：适于从具有第一速度的第一水平输送机接收物体并将物体供给具有第二速度的第二水平输送机并将物体定位在第二输送机上的预定位置的过渡装置，其中，第一输送机具有可变间隔，并且其中过渡装置适于根据第一输送机上的物体的位置从第一速度逐渐加速到第二速度。本发明的优点是具有与第一输送机可变间隔的物体可以在预定位置处定位在第二输送机上。

8. 发明申请

WO2009056671A1 METHOD FOR INHIBITING ANGIOGENESIS OR FOR TREATMENT OF CANCER 审中-公开
标题翻译：抑制血液生成或治疗癌症的方法
公开(公告)号：WO2009056671A1
公开(公告)日：2009-05-07
申请号：PCT/FI2008/050577
申请日：2008-10-15
申请人： FARON VENTURES OY , SALMI, Marko , JALKANEN, Sirpa
发明人： SALMI, Marko , JALKANEN, Sirpa
IPC分类号： A61K31/713 , A61K48/00 , A61K31/00 , A61K39/395 , C12N9/06 , C12N15/53 , C12N15/11 , A61P35/00
CPC分类号： A61K31/713 , A01K2267/0331 , A61K31/00 , A61K2039/505 , C07K16/28 , C12N9/0022 , C12Y104/03021
摘要： The invention concerns a method for inhibiting angiogenesis or for treating or preventing cancer or cancer metastasis in an individual. The method is based on the administration of an agent capable of counteracting the influence of or for down- regulating the expression of the vascular adhesion protein 1 (VAP-I). The inhibition of the catalytic activity of VAP-I is especially desirable for inhibiting angiogenesis and for treating or preventing of cancer or cancer metastasis.
摘要翻译：本发明涉及一种抑制个体的血管生成或治疗或预防癌症或癌症转移的方法。该方法基于能够抵抗血管粘附蛋白1（VAP-1）的表达的影响或用于下调血管粘附蛋白1（VAP-1）的表达的试剂的施用。 VAP-1的催化活性的抑制对于抑制血管发生和治疗或预防癌症或癌症转移是特别需要的。

9. 发明申请

WO2006134203A1 COMPOUNDS FOR TREATING OR PREVENTING AMINE OXIDASE RELATED DISEASES OR DISORDERS 审中-公开
标题翻译：用于治疗或预防胺氧化酶相关疾病或病症的化合物
公开(公告)号：WO2006134203A1
公开(公告)日：2006-12-21
申请号：PCT/FI2006/000188
申请日：2006-06-12
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , JALKANEN, Markku , SALMI, Marko
发明人： JALKANEN, Sirpa , JALKANEN, Markku , SALMI, Marko
IPC分类号： A61K31/7088 , C12N15/11 , C07H21/02 , C12N9/06
CPC分类号： C12N15/1138 , C12N2310/14 , C12Y104/03021
摘要： This invention relates to small interfering RNAs (siRNAs) that down regulates the expression of vascular adhesion protein 1 (VAP-1) for prevention or treatment of a disease or disorder that benefits from the inhibition or down regulation of VAP-1. Pharmaceutical compositions comprising said siRNAs in combination with pharmaceutically acceptable carriers are also included. Furthermore, the invention concerns expression vectors comprising nucleic acids encoding the siRNA duplexes or the antisense strands of said duplexes in a manner which allows expression of said siRNA duplexes or antisense strands within a mammalian cell. Pharmaceutical compositions comprising said expression vectors in combination with pharmaceutically acceptable carriers are also included.
摘要翻译：本发明涉及下调调节血管粘附蛋白1（VAP-1）在预防或治疗受益于VAP-1的抑制或下调的疾病或病症中的表达的小干扰RNA（siRNA）。还包括包含所述siRNA与药学上可接受的载体组合的药物组合物。此外，本发明涉及包含编码所述双链体的siRNA双链体或反义链的核酸的表达载体，其允许所述siRNA双链体或反义链在哺乳动物细胞内表达。还包括包含所述表达载体与药学上可接受的载体组合的药物组合物。

10. 发明申请

WO2003093319A1 NOVEL HUMANIZED ANTI-VAP-1 MONOCLONAL ANTIBODY 审中-公开
标题翻译：新型人造血管-1抗体单克隆抗体
公开(公告)号：WO2003093319A1
公开(公告)日：2003-11-13
申请号：PCT/FI2003/000330
申请日：2003-04-28
申请人： BIOTIE THERAPIES CORPORATION , JALKANEN, Sirpa , SALMI, Marko , LAUKKANEN, Marja-Leena , CLARK, Michael, Ronald
发明人： JALKANEN, Sirpa , SALMI, Marko , LAUKKANEN, Marja-Leena , CLARK, Michael, Ronald
IPC分类号： C07K16/28
CPC分类号： C07K16/28 , A61K2039/505 , C07K2317/24 , C07K2317/565
摘要： Chimeric anti-VAP-1 antibodies and fragments thereof are disclosed. Nucleic acids encoding anti-VAP-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-VAP-1 antibodies are also given. Pharmaceutical compositions comprising said antibodies and therapeutic uses thereof are also disclosed.
摘要翻译：公开了嵌合抗VAP-1抗体及其片段。还给出编码抗VAP-1抗体或其片段的核酸，以及掺入这些核酸用于重组表达抗VAP-1抗体的表达载体和宿主细胞。还公开了包含所述抗体的药物组合物及其治疗用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式